Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Announces Target Price $210
Mizuho Securities analyst Ann Hynes maintains $Charles River(CRL.US)$ with a hold rating, and sets the target price at $210.According to TipRanks data, the analyst has a success rate of 63.3% and a
Charles River Comparative Study Reveals That Kytopen's Flowfect Tx Platform Outperforms Conventional Electroporation Platforms
Charles River Laboratories, CEBINA Partner to Accelerate Neurodegenerative Drug Development
Unusual Options Activity: WBD, CRL and Others Attract Market Bets, WBD V/OI Ratio Reaches 73.9
EST Sep 16th Morning Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Shareholders in Charles River Laboratories International (NYSE:CRL) Are in the Red If They Invested Three Years Ago
CRL Stock May Benefit From New Neuroscience Research Collaboration
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
Higher Interest Environment Negatively Impacted Charles River Laboratories (CRL)
Zacks.com Featured Highlights Include Vertiv, Charles River Associates, Cabot, Leidos and HCA Healthcare
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Neptune Flood Reaches Milestone of 200,000 Policies and $250 Million of Premium in Force
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
Super Micro's Precipitous August Stock Selloff Can Be Summed up by These Stats
Morgan Stanley Fund: Will the pharmaceutical stocks "counterattack" as the Federal Reserve cuts interest rates?
Morgan Stanley Fund said that if the Federal Reserve cuts interest rates, risk appetite for funds may increase, and innovative drugs with higher growth potential may receive more risk capital favor in the short to medium term, gaining some upward momentum.
Charles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$205?